Cara Therapeutics | CARA - Assets


Cara Therapeutics reported $25.82M in Assets for its fiscal quarter ending in March of 2026.





Assets Change Date
Acadia Pharmaceuticals USD 1.74B 137.67M Jun/2026
Alterity Therapeutics Limited AUD 37.98M 15.78M Dec/2025
Cara Therapeutics USD 25.82M 6.26M Mar/2026
Cassava Sciences USD 108.37M 9.99M Mar/2026
Chugai Pharma JPY 2.45T 184.81B Jun/2026
Cipla INR 424.96B 23.32B Mar/2026
Clal Biotechnology ILS 158.39M 24.3M Dec/2023
Compugen USD 145.86M 10.71M Mar/2026
CSL USD 37.9B 1.5B Dec/2025
Grifols EUR 23.15B 142.7M Dec/2025
Halozyme Therapeutics USD 2.58B 95.31M Jun/2026
J&J USD 201.06B 167M Jun/2026
Neurocrine Biosciences USD 5.36B 452.9M Jun/2026
Pacira USD 1.24B 35.44M Jun/2026
Pfizer USD 201.13B 6.49B Jun/2026
RedHill Biopharma USD 25.34M 6.97M Dec/2025
Supernus Pharmaceuticals USD 1.43B 72.62M Jun/2026
Vanda Pharmaceuticals USD 488.95M 112.19M Dec/2025